CA-IX Specific Antibodies for ADC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CA-IX antibodies lack specificity and efficacy as ADC candidates, with limited understanding of their ability to function effectively due to design challenges and off-target effects, necessitating the development of high-affinity antibodies that can specifically target CA-IX without causing toxicity or therapeutic resistance.
Innovation Solution
Development of high-affinity Carbohydrate Anhydrase IX-specific antibodies and their fragments, specifically designed to bind the extracellular domain of CA-IX, engineered as chimeric antibodies with optimized complementarity determining regions (CDRs) for enhanced internalization and use as antibody-drug conjugates, minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-CA-IX antibodies are used, then CA-IX binding is achieved, but specificity and efficacy as ADC candidates are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the complementarity determining regions (CDRs) of the antibodies to achieve high-affinity binding to CA-IX. The CDR sequences are specifically engineered to enhance binding affinity and specificity, thereby improving the antibody's effectiveness as an ADC candidate while reducing off-target effects.
2Reliability
If antibodies are designed for high affinity binding to CA-IX, then therapeutic efficacy is improved, but off-target effects and toxicity may increase
Solution Approach 1:
The patent applies local quality by precisely engineering specific regions (CDRs) of the antibody to interact with CA-IX, while keeping the rest of the antibody structure optimized for safety and reduced off-target effects. This localized optimization ensures high therapeutic efficacy at the target site while minimizing harmful effects elsewhere in the body.
3Productivity
If antibody internalization is enhanced, then ADC potential is improved, but design complexity increases
Solution Approach 1:
The patent applies parameter changes by modifying the CDR sequences to enhance internalization efficiency. The optimized CDR regions facilitate better binding to CA-IX and subsequent internalization, thereby improving ADC potential without requiring complex structural modifications throughout the entire antibody molecule.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.